What if We're Using GLP-1 Medications All Wrong?

Drugs like Ozempic, Wegovy, and Mounjaro are transforming the landscape of medical weight loss, but could their side effects be a sign that we’re not harnessing their full therapeutic potential?

In this eye-opening conversation, Dr. Ben Bikman, metabolic health researcher and professor at BYU, joins Dr. Bret Scher to explore a powerful new framework: using GLP-1 medications at low doses and for short durations to help curb carbohydrate cravings, break addictive eating cycles, and support long-term metabolic health.

Rather than prescribing high doses indefinitely, Dr. Bikman proposes a more targeted approach:

• Microdosing GLP-1s to enhance satiety and reduce cravings for processed carbs
• Using the medication as a temporary metabolic tool to support transitions to lower-carb diets
• Reducing long-term risks such as muscle loss, mood changes, and diminishing effectiveness
• Emphasizing the importance of habit change, insulin regulation, and muscle preservation

This conversation reimagines GLP-1s not as a lifelong solution, but as a catalyst for sustainable, low-insulin lifestyles, aligned with ketogenic and metabolic therapies.

📌 Could a 90-day microdosing protocol replace years of medication?

Learn how this metabolic-first strategy could empower patients to reclaim their health, without becoming dependent on medication for life.

Expert Featured:

• Dr. Benjamin Bikman
• https://x.com/BenBikmanPhD
• benbikman.com
• insuliniq.com

Papers/Articles Mentioned:

-https://www.washingtontimes.com/news/2025/may/27/microdosing-glp-1-drugs-could-solve-americas-carbohydrate-crisis/

-https://pubmed.ncbi.nlm.nih.gov/8984033/

Follow our channel for more information and education from Bret Scher, MD, FACC, including interviews with leading experts in Metabolic Psychiatry.

Learn more about metabolic psychiatry and find helpful resources at https://metabolicmind.org/